Cryolife Inc (NYSE:CRY) has earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the company, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Analysts have set a 12-month consensus target price of $13.50 for the company and are expecting that the company will post $0.05 EPS for the current quarter, according to Zacks. Zacks has also assigned Cryolife an industry rank of 101 out of 265 based on the ratings given to its competitors.
Shares of Cryolife (NYSE:CRY) opened at 10.78 on Monday. The company has a market capitalization of $306.73 million and a P/E ratio of 99.81. The firm has a 50-day moving average of $10.57 and a 200 day moving average of $10.53. Cryolife has a 1-year low of $9.41 and a 1-year high of $12.29.
Cryolife (NYSE:CRY) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.10 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.01 by $0.09. The firm had revenue of $36.70 million for the quarter, compared to analysts’ expectations of $38.17 million. During the same period in the previous year, the company earned $0.08 EPS. The company’s quarterly revenue was down 1.1% on a year-over-year basis. On average, equities research analysts expect that Cryolife will post $0.09 earnings per share for the current year.
The business also recently announced a quarterly dividend, which was paid on Friday, December 18th. Stockholders of record on Friday, December 11th were given a $0.03 dividend. The ex-dividend date of this dividend was Wednesday, December 9th. This represents a $0.12 annualized dividend and a dividend yield of 1.11%.
In other news, CFO David Ashley Lee sold 11,800 shares of the firm’s stock in a transaction dated Monday, November 30th. The shares were sold at an average price of $11.03, for a total value of $130,154.00. Following the completion of the sale, the chief financial officer now directly owns 243,969 shares of the company’s stock, valued at approximately $2,690,978.07. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.
Several equities research analysts have weighed in on CRY shares. Piper Jaffray reissued an “overweight” rating and set a $15.00 price target on shares of Cryolife in a research report on Thursday, December 24th. Zacks Investment Research raised shares of Cryolife from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Tuesday, December 22nd. Finally, TheStreet raised shares of Cryolife from a “hold” rating to a “buy” rating in a research report on Wednesday, November 25th.
CryoLife, Inc. (NYSE:CRY) is a medical device company. The Company is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment includes external revenues from product sales of BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, HeRO Graft, and ProCol. The Preservation Services segment includes external services revenues from the preservation of cardiac and vascular tissues. The Company’s product BioGlue, is a polymer consisting of bovine blood protein and an agent for cross-linking proteins, which was developed for use in cardiac, vascular, pulmonary, and surgical applications. The Company developed BioFoam to seal organs, such as the liver, and for use in cardiovascular surgeries, and provide hemostasis in penetrating wounds and trauma.
For more information about research offerings from Zacks Investment Research, visit Zacks.com